Grastim™
Filgrastim
Granulocyte Colony Stimulating factor (Oncology)
Indication:
1. Cancer patients receiving myelosuppressive chemotherapy: Filgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. 2. Patients with Acute Myeloid Leukemia, receiving Induction or consolidation chemotherapy: Filgrastim is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. 3. Cancer patients receiving bone marrow transplant:
Preparation:
GrastimTM: Each box contains 1 pre-filled syringe of 300 mcg (30 MU) Filgrastim in Alu-Alu Blister pack.
